Osteoporosis is characterized by low bone mass with skeletal fragility and an increased risk
of fracture. This bone loss is brought about by an imbalance between bone resorption and …

Ketoconazole has been widely used as a strong cytochrome P450 (CYP) 3A (CYP3A) inhibitor
in drug–drug interaction (DDI) studies. However, the US Food and Drug Administration …

[ 18 F]MK-9470 is a selective, high-affinity, inverse agonist (human IC 50 , 0.7 nM) for the
cannabinoid CB1 receptor (CB1R) that has been developed for use in human brain imaging. …

Cathepsin K (CatK) is a cysteine protease abundantly expressed by osteoclasts and localized
in the lysosomes and resorption lacunae of these cells. CatK is the principal enzyme …

Inhibition of cathepsin K (CatK) is a potential new treatment for osteoporosis. In two double‐blind,
randomized, placebo‐controlled phase I studies, postmenopausal female subjects …

Prostate cancer is the most common visceral malignancy in men. As the tumor is testosterone
dependent, a frequent treatment modality involves therapy with GnRH agonists (GnRH-a) …

Aims Rosuvastatin and pitavastatin have been proposed as probe substrates for the organic
anion‐transporting polypeptide ( OATP ) 1 B , but clinical data on their relative sensitivity …

Background Odanacatib, a cathepsin K inhibitor, reduces bone resorption while maintaining
bone formation. Previous work has shown that odanacatib increases bone mineral density …

The α V β 3 integrin (vitronectin receptor) plays a pivotal role in bone resorption. We
hypothesized that L-000845704, an α V β 3 integrin antagonist, would potently inhibit bone …

A microdose cocktail containing midazolam, dabigatran etexilate, pitavastatin, rosuvastatin,
and atorvastatin has been established to allow simultaneous assessment of a perpetrator …